Thus, the use of dutasteride for Pca chemoprevention remains controversial.[9] In addition, since dutasteride reduces PSA levels by an average of about 50%, it is recommended that PSA levels in dutasteride-treated patients be evaluated at twice the PSA level,[10] making prostate biopsy decisions based on PSA levels more difficult. Here, KLK3 is linked to posterior cortical atrophy.